Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
about
An analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitorsPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionDrug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.Clinically relevant drug-drug interactions between antiretrovirals and antifungalsPlasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.Once-daily abacavir in place of twice-daily administration.Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agentsSystems Approach to targeted and long-acting HIV/AIDS therapy.Drug interactions in the management of HIV infection: an update.Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients.DNA polymerases as therapeutic targetsTenofovir: what have over 1 million years of patient experience taught us?Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activityHormonal contraceptive use in HIV-infected women using antiretroviral therapy: A Systematic review.Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.Interlaboratory measurement differences in intracellular carbovir triphosphate concentrations in HIV-infected patients: sources of variability in processing, shipping, and quantitation.Survival probability and predictors of mortality and retention in care among patients enrolled for first-line antiretroviral therapy, Andhra Pradesh, India, 2008-2011.Precision medicine for HIV: where are we?
P2860
Q28474361-688E5C68-9DBF-4405-99E8-35E52CE38291Q28481276-B75CF968-F14E-466B-A717-5C907593FAC1Q30249113-FAE9489C-66FE-491D-97A1-70E10B22B853Q34495644-C38731F4-50C8-4D3E-901E-06A34409B58BQ34869449-6C51F791-378C-49CA-B9F0-A630F6E1590FQ35139522-0D767FCA-F725-4696-B885-B5CB2D695216Q35892563-3B66583B-3C26-4488-94CA-8F417F84A442Q36075954-63B7E56F-1629-4737-A5B3-F06AE10D49DFQ36097686-2D2E311E-EA06-4725-84A4-CDB38FBA2321Q36163198-96E0566A-898A-4EA4-ACCB-4890A62176C3Q36583732-AA2F62BF-6542-447E-B0DD-D6BA4317DE05Q36723853-1C7C16B7-0540-4177-8E8D-2F58165442F9Q36760224-D9236537-AA60-4C53-BE3B-6E503EB4643BQ36783298-925D5419-E852-43D4-8698-7CF65F5C672AQ37000733-B4648854-BB98-4F75-915F-60C4EA3F0248Q37077340-B1E87117-9B2A-4918-81B7-1668A3C05037Q37111444-8DDB8DC7-05E2-4627-9E65-EF22B463D01CQ37216862-63F187D1-256B-4681-864D-C6DA4475213BQ37244357-CCF3E9F7-4512-49BC-8107-F2F8F1F59CBFQ37338133-50A47EA7-0B5D-4DDD-BDAD-99C0287390C2Q37503472-662A32BB-6FF4-443E-B876-707191C9196CQ38207924-6E91D854-D64E-4D18-8E6C-8E88C9F9EFF6Q39634357-9F7D8AEE-B830-43D7-9D1B-C2F4A3DD2ADFQ41694386-1653551E-417A-44EA-8020-4AEACE64C73AQ42201355-12B16723-2AD2-493B-BEB3-87FB40FCD2B1Q43447907-499F4820-8D79-41DC-A8C6-892D24F4CB1DQ43499781-AC219321-2290-4D66-8980-14ADCA725315Q47569821-BD5A1DE5-AA5A-4084-9B7A-914CE6F6021E
P2860
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@ast
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@en
type
label
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@ast
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@en
prefLabel
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@ast
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@en
P1476
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
@en
P2093
Peter J Piliero
P304
P356
10.1097/01.QAI.0000137001.40505.56
P407
P478
37 Suppl 1
P577
2004-09-01T00:00:00Z